Broad files U.S. Court of Appeals for the Federal Circuit (CAFC) Appellee Brief

In response to the Doudna-Charpentier team’s Appellant Brief, the Broad primarily argues in its Appellee Brief that the Patent Trial and Appeal Board (PTAB) judgment was based on substantial evidence; and that the PTAB did not commit legal errors in its ruling and that it considered all relevant evidence. The Broad argues that there was not a reasonable expectation of success after the Jinek 2012 paper that the CRISPR-Cas9 system would have worked in eukaryotic cells.


Download the Broad Appellee Brief


Sign up to receive updates from the CRISPR Collective

Related News

U.S. Patent and Trademark Office issued U.S. Patent No. 10,266,850 (‘the ‘850 patent), to The Regents of the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier
European Patent Office (EPO) awarded the Doudna-Charpentier team a broad CRISPR-Cas9 patent (EP Patent No. 3 401 400)
U.S. patent office issued third CRISPR patent to CVC; indicates it will issue a fourth
Read moreArrow-down